Cancer Family
Malignant Endocrine Neoplasm
CI-CAN-00000230Explore in graph →
576 active trials16 approved drugs58 evidence items
- NCIt
- C3575
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000230Explore in graph →
Clinical trials
1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (238)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06807632 | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | recruiting | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04171622 | Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | active not recruiting | Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 |
| NCT04623801 | Laser Ablation of Papillary Thyroid Microcarcinoma | active not recruiting | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04280081 | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation(LIBRETTO-321) | active not recruiting | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT06056895 | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma(TRICK-MCC) | active not recruiting | Phase 2 | 12 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT06941480 | A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate | not yet recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07468656 | SCLC Tarlatamab Blood Collection | not yet recruiting | — | 25 | Duke UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT05879978 | A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | active not recruiting | Phase 1 | 45 | Boehringer IngelheimINDUSTRY | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06486428 | Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies(SUCCEED) | active not recruiting | — | 22 | Addario Lung Cancer Medical InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07713901 | Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma | enrolling by invitation | — | 93,600,000 | Novo Nordisk A/SINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)(PULSE) | recruiting | Phase 4 | 107 | Anhui Provincial Cancer HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03896503 | Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs | active not recruiting | Phase 2 | 104 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03914300 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT05947500 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial | active not recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07129252 | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors(BRAVESST2) | recruiting | Phase 1 / Phase 2 | 150 | Crinetics Pharmaceuticals Inc.INDUSTRY | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07402343 | Tarlatamab for SCLC Brain Metastases(T-BRAIN) | recruiting | Phase 2 | 35 | Maastricht University Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738159 | Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 92 | West China HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT05957510 | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment | active not recruiting | Phase 2 | 66 | Guangdong Association of Clinical TrialsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 35 | Bindu R PotugariOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | not yet recruiting | Phase 1 | 120 | Treeline Biosciences, Inc.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02595424 | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | active not recruiting | Phase 2 | 67 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06095583 | Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 3 | 756 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 6 | Jul 27, 2026 | clinicaltrials |
| NCT06992609 | Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.(ALBORAN) | active not recruiting | Phase 3 | 68 | AstraZenecaINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07502300 | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) | recruiting | Phase 3 | 562 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07728955 | A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy(SCLC) | not yet recruiting | Phase 3 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT03181100 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06931626 | Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer | recruiting | Phase 1 | 10 | Nerviano Medical SciencesINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | active not recruiting | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04471974 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 61 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05882058 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | recruiting | Phase 2 | 204 | Boehringer IngelheimINDUSTRY | 12 | Jul 23, 2026 | clinicaltrials |
| NCT06437509 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 66 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04877613 | GFRα4 CAR T Cells in MTC Patients | active not recruiting | Phase 1 | 9 | University of PennsylvaniaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07253142 | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer | recruiting | Phase 2 | 120 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07559786 | A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy(ARL-LS-SCLC) | recruiting | Phase 2 | 200 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712094 | AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer | not yet recruiting | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03043872 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)(CASPIAN) | active not recruiting | Phase 3 | 987 | AstraZenecaINDUSTRY | 23 | Jul 16, 2026 | clinicaltrials |
| NCT03892993 | Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers | recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05100095 | Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 11, 2026source: clinicaltrials